Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adoptive Immunotherapy for EBV-Induced Lymphoproliferative Disease
NCT00005606Phase 2Completed
- Sponsor
- Northwestern University
- Start
- Feb 2000
- Primary completion
- Sep 2003
- Modality
- Adoptive Cell Transfer
- Countries
- 1
01
Overview
A Phase 2 trial of Epstein-Barr virus specific cytotoxic T lymphocytes in Post-Transplant Lymphoproliferative Disorder (PTLD), Epstein-Barr virus infection, sponsored by Northwestern University. Started Feb 2000; status: completed.
02
Drugs
Epstein-Barr virus specific cytotoxic T lymphocytes
03
Conditions
Post-Transplant Lymphoproliferative Disorder (PTLD)Epstein-Barr virus infection
Beyond the preview
Go deeper on NCT00005606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005606.